Merck & Co., Inc.
2000 Galloping Hill Road
About Merck & Co., Inc.
For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.
Founder: George Merck
CEO: Kenneth Frazier
CFO: Robert Davis
Please click here for Merck job opportunities.
Please click here for clinical trial information.
Tweets by Merck
2524 articles with Merck & Co., Inc.
Government officials say they are now certain they know who launched the NotPetya cyberwar that slammed operations at Merck last year.
AstraZeneca and Merck announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).
Alzheimer's drug development took another hit.
The 60-year-old chemist has been charged with stealing 219.79 grams of potassium cyanide from a Merck facility in Pennsylvania.
Parkinson’s Institute and Clinical Center Collaborates with Merck to Evaluate LRRK2 Kinase Inhibition in Preclinical Model of Parkinson’s Disease
The Parkinson’s Institute and Clinical Center has entered into a collaboration with Merck, known as MSD outside the United States and Canada, to study the effects of LRRK2 kinase inhibitors on non-motor symptoms in a preclinical model of gastrointestinal (GI) dysfunction in Parkinson’s disease.
Worldwide sales were $10.4 billion for the fourth quarter of 2017, an increase of 3 percent compared with the fourth quarter of 2016, including a 1 percent positive impact from foreign exchange.
Since 2013, Dr. Perlmutter has served as executive vice president of Merck and president of Merck Research Laboratories.
Prokaryotics Announces Licensing Agreement With Merck for Novel Investigational Antibiotic Candidates
Specific terms of the agreement were not disclosed.
Mr. Thulin will stand for election with the company’s other directors in connection with Merck’s Annual Meeting of Shareholders on May 22, 2018.
Marshall co-founded more than a decade ago, and which was acquired by Sosei in 2015.
Merck today announced that the Board of Directors has declared a quarterly dividend of $0.48 per share of the company’s common stock for the second quarter of 2018.
First-Time Data for Merck’s KEYTRUDA (pembrolizumab) in Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC) to be Presented at 2018 ASCO GI Symposium
Merck today announced findings from the registrational phase 2 KEYNOTE-224 trial investigating the use of KEYTRUDA (pembrolizumab).
Astrazeneca Release: LYNPARZA (olaparib) Receives Approval in Japan for the Treatment of Advanced Ovarian Cancer
AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Japanese Ministry of Health, Labour and Welfare has approved LYNPARZA® (olaparib) tablets (300mg twice daily) for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer, regardless of their BRCA mutation status, who responded to their last platinum-based chemotherapy.
1/17/2018Despite some safety concerns such as severe diarrhea, the FDA approved Puma's breast cancer drug Nerlynx in July 2017.
Amgen's migraine drug Aimovig continues to impress with its efficacy in late-stage studies.
Merck's Keytruda has done it again.
Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer.
Here is a look at key takeaways from presentations made by four major pharma and biotech stocks at the annual J.P. Morgan healthcare conference.
The Phase II part of the trial is underway with patients who had select solid tumors with 0-2 prior lines of systemic therapy.
A look at the lucky drugs that have been hailed a breakthrough by the FDA.